WASHINGTON – On the same day that Gilead Sciences Inc. revealed it had submitted a new drug application to the FDA to market a single combination pill of Truvada (emtricitabine and tenofovir disoproxil fumarate) plus Tibotec Pharmaceuticals Ltd.'s TMC278 (rilpivirine hydrochloride) as a treatment for HIV-1 infection in adults, researchers reported results showing that a daily pre-exposure prophylactic (PrEP) dose of Truvada cut the risk of HIV infection by 44 percent. (BioWorld Today) Read More
